The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

(2016) Yasuhiro Asahina et al.   HEPATOLOGY RESEARCH

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

(2015) Maria Buti et al.   CLINICAL INFECTIOUS DISEASES

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

(2015) Hiromitsu Kumada et al.   HEPATOLOGY

The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

(2015) Toshiki Kan et al.   JOURNAL OF GASTROENTEROLOGY

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

(2015) Xavier Forns et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Mark Sulkowski et al.   LANCET

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

(2015) David Roth et al.   LANCET

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

(2015) Jürgen K Rockstroh et al.   Lancet HIV

The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis

(2014) Michael P. Manns et al.   GASTROENTEROLOGY

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Global epidemiology and genotype distribution of the hepatitis C virus infection

(2014) Erin Gower et al.   JOURNAL OF HEPATOLOGY

Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

(2013) Craig A. Coburn et al.   ChemMedChem

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

(2012) Vincenzo Summa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolving epidemiology of hepatitis C virus

(2010) D. Lavanchy   CLINICAL MICROBIOLOGY AND INFECTION

Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan

(2010) Hobyung Chung et al.   INTERVIROLOGY